Despite a global pandemic that continued to inflict chaos and confusion on the world, resulting in fewer cancer screenings and delayed surgeries, remarkable lung cancer treatment advancements were made in… Click to show full abstract
Despite a global pandemic that continued to inflict chaos and confusion on the world, resulting in fewer cancer screenings and delayed surgeries, remarkable lung cancer treatment advancements were made in 2021. From immunotherapy in the adjuvant setting to the approval of the first‐in‐class, highly selective inhibitor of KRAS G12C, these treatment advances have significant clinical impact in patients with lung cancer.
               
Click one of the above tabs to view related content.